文献速递白血病MDS 与骨髓增殖性肿瘤

靶向下一代测序与世界卫生组织定义的非典型慢性髓性白血病危险因素识别

Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
PubMed 文献 · Am J Hematol · 2017-04-29

该研究对25例世界卫生组织定义的非典型慢性髓性白血病患者进行靶向测序,中位年龄70岁,84%为男性,全部检出基因突变。中位总生存10.8个月,多因素分析显示高龄、低血红蛋白和TET2突变保留预后意义,并据此构建风险模型将患者分为低危和高危,中位总生存分别为18个月和7个月。

要点

  • 全部25例非典型慢性髓性白血病患者均检出基因突变,60%存在>1个突变。
  • 多因素分析中高龄(>67岁)、血红蛋白<10 gm/dL和TET2突变与生存不良独立相关。
  • 基于上述3项危险因素的风险模型将患者分为低危(0-1个危险因素)和高危(≥2个危险因素),中位总生存分别为18个月和7个月。

核心结论

  • 高龄、低血红蛋白和TET2突变是非典型慢性髓性白血病患者总生存的独立不良预后因素。
  • 基于年龄>67岁、血红蛋白<10 gm/dL和TET2突变构建的风险加权模型可将患者分为低危和高危两组,中位总生存分别为18个月和7个月。

研究设计与样本

  • 研究纳入25例经世界卫生组织定义且具有分子注释的非典型慢性髓性白血病患者,中位年龄70岁,84%为男性。
  • 采用靶向下一代测序检测基因突变,并进行生存分析。

主要发现

  • 细胞遗传学异常见于36%的患者,基因突变见于100%的患者。
  • 突变频率为ASXL1 28%、TET2 16%、NRAS 16%、SETBP1 12%、RUNX1 12%、ETNK1 8%、PTPN11 4%。
  • 15例(60%)患者有>1个突变,9例(36%)有≥3个突变。
  • 中位总生存为10.8个月,末次随访(中位11个月)时记录到17例(68%)死亡和2例(8%)白血病转化。
  • 单因素分析中,高龄(P = .02)、低血红蛋白(P = .01)、红细胞输注依赖(P = .03)、高白细胞计数(P = .02)、TET2突变(P = .03)、NRAS突变(P = .04)、PTPN11突变(P = .02)和≥3个基因突变(P = .006)与生存不良相关;ASXL1、SETBP1和ETNK1突变未影响总生存。

关键数值与推荐

  • 风险模型将年龄>67岁、血红蛋白<10 gm/dL和TET2突变各计为一个危险因素。
  • 低危组(0-1个危险因素)中位总生存为18个月,高危组(≥2个危险因素)中位总生存为7个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atypical chronic myeloid leukemia (aCML) is an aggressive myeloid neoplasm with overlapping features of myelodysplastic syndromes (prominent granulocytic dysplasia) and myeloproliferative neoplasms (neutrophilic leukocytosis). We studied 25 molecularly-annotated and World Health Organization defined aCML patients; median age 70 years, 84% males. Cytogenetic abnormalities were seen in 36% and gene mutations in 100%. Mutational frequencies were, ASXL1 28%, TET2 16%, NRAS 16%, SETBP1 12%, RUNX1 12%, ETNK1 8%, and PTPN11 4%. Fifteen patients (60%) had >1 mutation, while 9 (36%) had ≥3. The median overall survival (OS) was 10.8 months and at last follow up (median 11 months), 17 (68%) deaths and 2 (8%) leukemic transformations were documented. On univariate analysis, survival was adversely impacted by advanced age (P = .02), low hemoglobin (P = .01), red blood cell transfusion dependence (P = .03), high white blood cell count (P = .02), TET2 (P = .03), NRAS (P = .04), PTPN11 (P = .02) mutations and the presence of ≥3 gene mutations (P = .006); ASXL1, SETBP1, and ETNK1 mutations did not impact OS. In multivariable analysis, advanced age (P = .003) [age >67: HR 10.1, 95% CI 1.3-119], low hemoglobin (P = .008) [HB< 10 gm/dL: HR 8.2, 95% CI 1.6-23.2] and TET2 mutations (P = .01) [HR 8.8, 95% CI 1.6-47.7] retained prognostic significance. We then used age >67 years, hemoglobin <10 gm/dL and the presence of TET2 mutations (each counted as one risk factor) to create a hazard ratio weighted prognostic model; effectively stratifying patients into two risk categories, low (0-1 risk factor) and high (≥2 risk factors), with median OS of 18 and 7 months, respectively.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017. PMID: 28314085. doi:10.1002/ajh.24722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。